Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 108Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Leukemia 15Lymphoma 14Burkitt Lymphoma 14Recurrence 10Lymphoma, Non-Hodgkin 10Lymphoma, Mantle-Cell 10Waldenstrom Macroglobulinemia 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Immunoglobulin Light-chain Amyloidosis 8Neoplasms, Plasma Cell 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell, Marginal Zone 6Smoldering Multiple Myeloma 5Neoplasms 5Lymphoma, Follicular 5Leukemia, Biphenotypic, Acute 5Hodgkin Disease 5Neoplasm Metastasis 4Nausea 4Breast Neoplasms 4Vomiting 3Renal Insufficiency 3Lymphoma, Large-Cell, Anaplastic 3Leukemia, Plasma Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hematologic Neoplasms 3Brain Neoplasms 3Blast Crisis 3

Interventions

siltuximab 3tocilizumab 1talquetamab 1obinutuzumab 1glofitamab 1axicabtagene ciloleucel 1Oxaliplatin 1Interleukin 1 Receptor Antagonist Protein 1Gemcitabine 1Gelsolin 1Dexamethasone 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Cytokine Release Syndrome × Calcium Dobesilate × Clear all
NCT05972135 2026-04-22

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

SCRI Development Innovations, LLC

Phase 2 Recruiting
100 enrolled
Plasma cell

Cytokine Release Syndrome, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡